Logo image of MAAT.PA

MAAT PHARMA SACA (MAAT.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:MAAT - FR0012634822 - Common Stock

4.7 EUR
-0.2 (-4.08%)
Last: 1/14/2026, 11:23:24 AM

MAAT.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap88.13M
Revenue(TTM)3.92M
Net Income(TTM)-31.09M
Shares18.75M
Float7.44M
52 Week High8.46
52 Week Low3.55
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.15
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2021-11-08
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
MAAT.PA short term performance overview.The bars show the price performance of MAAT.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

MAAT.PA long term performance overview.The bars show the price performance of MAAT.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of MAAT.PA is 4.7 EUR. In the past month the price increased by 13.43%. In the past year, price decreased by -38.75%.

MAAT PHARMA SACA / MAAT Daily stock chart

MAAT.PA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to MAAT.PA. When comparing the yearly performance of all stocks, MAAT.PA is a bad performer in the overall market: 87.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MAAT.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA. MAAT.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MAAT.PA Financial Highlights

Over the last trailing twelve months MAAT.PA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -4.65% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.6%
ROE -374.74%
Debt/Equity 1.43
Chartmill High Growth Momentum
EPS Q2Q%7.57%
Sales Q2Q%41.02%
EPS 1Y (TTM)-4.65%
Revenue 1Y (TTM)52.55%

MAAT.PA Forecast & Estimates

12 analysts have analysed MAAT.PA and the average price target is 17.12 EUR. This implies a price increase of 264.29% is expected in the next year compared to the current price of 4.7.

For the next year, analysts expect an EPS growth of -52.83% and a revenue growth 268.61% for MAAT.PA


Analysts
Analysts88.33
Price Target17.12 (264.26%)
EPS Next Y-52.83%
Revenue Next Year268.61%

MAAT.PA Ownership

Ownership
Inst Owners38.96%
Ins Owners1.43%
Short Float %N/A
Short RatioN/A

MAAT.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1AE.DE ARGENX SE 65.36 42.94B
ARGX.BR ARGENX SE 65.49 43.02B
22UA.DE BIONTECH SE-ADR N/A 22.41B
ABVX.PA ABIVAX SA N/A 8.33B
2X1.DE ABIVAX SA N/A 7.99B
GLPG.AS GALAPAGOS NV N/A 1.88B
GXE.DE GALAPAGOS NV N/A 1.88B
IVA.PA INVENTIVA SA N/A 961.78M
5CV.DE CUREVAC NV 6.71 876.36M
NANO.PA NANOBIOTIX N/A 873.18M
6IV.DE INVENTIVA SA N/A 834.75M
PHIL.MI PHILOGEN SPA 19.43 647.67M

Related stock screener links

About MAAT.PA

Company Profile

MAAT logo image Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

Company Info

MAAT PHARMA SACA

70 Avenue Tony Garnier

Lyon AUVERGNE-RHONE-ALPES FR

Employees: 63

MAAT Company Website

MAAT Investor Relations

Phone: 33428291400

MAAT PHARMA SACA / MAAT.PA FAQ

What does MAAT PHARMA SACA do?

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.


What is the stock price of MAAT PHARMA SACA today?

The current stock price of MAAT.PA is 4.7 EUR. The price decreased by -4.08% in the last trading session.


What is the dividend status of MAAT PHARMA SACA?

MAAT.PA does not pay a dividend.


What is the ChartMill rating of MAAT PHARMA SACA stock?

MAAT.PA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of MAAT stock?

MAAT PHARMA SACA (MAAT.PA) operates in the Health Care sector and the Biotechnology industry.


Should I buy MAAT stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MAAT.PA.


What is the employee count for MAAT stock?

MAAT PHARMA SACA (MAAT.PA) currently has 63 employees.